tadalafil has been researched along with da 8159 in 7 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (da 8159) | Trials (da 8159) | Recent Studies (post-2010) (da 8159) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 133 | 35 | 60 |
| Protein | Taxonomy | tadalafil (IC50) | da 8159 (IC50) |
|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.0082 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SB; Jeon, JH; Kang, KK; Kim, SH; Lee, SW; Park, JK; Zhao, C | 1 |
| Hwang, EC; Kim, SO; Park, K | 1 |
| Corona, G; Fusco, F; Mondaini, N; Razzoli, E; Rossi, A; Ungar, A | 1 |
| Carini, M; Corona, G; Gacci, M; Kaplan, SA; Maggi, M; McVary, KT; Mirone, V; Roehrborn, CG; Salvi, M; Serni, S; Vignozzi, L | 1 |
| Brock, G; Burnett, A; Ghanem, H; Giuliano, F; Glina, S; Hellstrom, W; Martin-Morales, A; Porst, H; Salonia, A; Sharlip, I | 1 |
| Alp, HH; Başbugan, Y; Ediz, L; Huyut, Z; Şekeroğlu, MR; Yildirim, S | 1 |
| Ding, S; Huang, X; Liu, L; Song, G; Wang, D; Xu, H | 1 |
5 review(s) available for tadalafil and da 8159
| Article | Year |
|---|---|
Prevalence and medical management of erectile dysfunction in Asia.
Topics: Adult; Aged; Asia; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prevalence; Purines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Topics: Algorithms; Carbolines; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Imidazoles; Impotence, Vasculogenic; Male; Men's Health; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alprostadil; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hypogonadism; Imidazoles; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Piperazines; Pyrimidines; Risk Factors; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Yohimbine | 2013 |
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Flavonoids; Humans; Neurons; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Purinones; Pyrimidines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride | 2019 |
1 trial(s) available for tadalafil and da 8159
| Article | Year |
|---|---|
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Aged; Carbolines; Erectile Dysfunction; Feasibility Studies; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Pyrimidines; Sulfonamides; Tadalafil; Treatment Outcome | 2011 |
1 other study(ies) available for tadalafil and da 8159
| Article | Year |
|---|---|
The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis.
Topics: Animals; Biomarkers; Bone and Bones; Bone Density; Chromatography, High Pressure Liquid; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Osteoporosis; Ovariectomy; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats, Wistar; Sulfonamides; Tadalafil; Treatment Outcome; Vardenafil Dihydrochloride | 2017 |